Updates on the Phase 3 Trial for an Antigen Specific Immune Tolerance Therapy for Type 1 Diabetes
Time: 8:30 am
day: Conference Day One
Details:
• Discussing considerations for late-stage clinical trials for antigen-specific approached to treating TD1
• Acknowledging regulatory requirements for precision medicine approaches for autoimmune diseases
• Navigating the use of a surrogate endpoint for BLA submission of precision medicine approaches
